9-cis-Vitamin-A(2)-saeure | 25428-49-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 9-cis-Vitamin-A(2)-saeure
• 英文别名: (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexa-1,3-dien-1-yl)nona-2,4,6,8-tetraenoic acid
• CAS: 25428-49-3
• 化学式: C₂₀H₂₆O₂
• 分子量: 298.425
• InChiKey: SYESMXTWOAQFET-ZVCIMWCZSA-N

物化性质

• 沸点：
  468.2±14.0 °C(predicted)
• 密度：
  1.027±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-cis-Vitamin-A(2)-saeure 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 生成 9-cis-Vitamin A(2)
  参考文献：
  名称：

  维生素A 2-合成中的合成物。2. Mitteilung。Die Darstellung von Vier sterisch ungehinderten Vitamin-A 2 -Isomeren

  摘要：

  由顺式和反式-脱氢-β制备了四种结晶的维生素A 2异构体，即全反式，13-顺式，9-顺式和9,13-二顺式，以及相应的酸和醛-亚乙炔基乙醛。

  DOI：

  10.1002/hlca.19620450216
• 作为产物：
  描述：

  (2E,4E)-3-methyl-5-(2,6,6-trimethylcyclohex-1-enyl)penta-2,4-dienoic acid 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 碘 、 potassium carbonate 作用下， 生成 9-cis-Vitamin-A(2)-saeure
  参考文献：
  名称：

  维生素A 2-合成中的合成物。2. Mitteilung。Die Darstellung von Vier sterisch ungehinderten Vitamin-A 2 -Isomeren

  摘要：

  由顺式和反式-脱氢-β制备了四种结晶的维生素A 2异构体，即全反式，13-顺式，9-顺式和9,13-二顺式，以及相应的酸和醛-亚乙炔基乙醛。

  DOI：

  10.1002/hlca.19620450216

文献信息

• Beneficial agent delivery system
  申请人：Conor Medsystems, Inc.

  公开号：EP1905477A1

  公开（公告）日：2008-04-02

  The application discloses a beneficial agent delivery system comprising: an implantable medical device (10) including a beneficial agent arranged for delivery to an implantation site within a patient, the beneficial agent configured to be modulated after implantation within the patient by an activating/deactivating means (200); and a selective modulation catheter having an activating/deactivating means (200) configured to activate or deactivate the beneficial agent on a first region of the medical device (10) to create a different delivery profile than the beneficial agent on a second region of the medical device (10).

  该申请公开了一种有益药剂递送系统，包括：可植入医疗设备（10），其中包括有益药剂，用于递送至患者体内的植入部位，有益药剂配置为在植入患者体内后通过激活/停用装置（200）进行调制；以及选择性调制导管，该导管具有激活/停用装置（200），配置为激活或停用医疗设备（10）第一区域上的有益药剂，以创建与医疗设备（10）第二区域上的有益药剂不同的递送曲线。
• Stent and method for reducing tissue damage after ischemic injury with thymosin B4
  申请人：Innovational Holdings, LLC

  公开号：EP1961435A2

  公开（公告）日：2008-08-27

  Methods and devices are provided for the delivery of thymosin β4 or an isoform thereof which reduces myocardial tissue damage due to ischemia. The thymosin β4 or isoform is delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the myocardial tissue. In addition to the treatment of ischemic injury, the thymosin β4, its analogues or derivatives can also be delivered from a stent to treat heart muscle loss from other causes including myocarditis, chronic heart failure, or prior AMI.

  本发明提供了胸腺肽β4或其异构体的给药方法和装置，可减少缺血引起的心肌组织损伤。胸腺肽 β4或其异构体被输送到心肌组织的给药时间足以减少心肌组织的缺血或再灌注损伤。除了治疗缺血性损伤，胸腺肽 β4、其类似物或衍生物还可通过支架输送，以治疗其他原因（包括心肌炎、慢性心力衰竭或先前的急性心肌梗死）造成的心肌损伤。
• Bioresorbable stent with beneficial agent reservoirs
  申请人：Conor Medsystems, Inc.

  公开号：EP2229919A2

  公开（公告）日：2010-09-22

  The invention provides an anti-restenotic drug for use in a method of reducing restenosis with a bioresorbable drug delivery stent, the method comprising: providing a drug delivery bioresorbable stent with a dosage of the anti-restenotic drug arranged within a plurality of openings in the stent without coating an exterior surface of the stent with the anti-restenotic drug; implanting the stent within an artery of a patient; and delivering the anti-restenotic drug from the stent to the artery at a minimum release rate of 1 percent of the total dosage of the drug on the stent per day throughout an entire administration period from the time of implantation of the stent until the time that substantially all the drug is released from the stent.

  本发明提供了一种抗再狭窄药物，用于使用生物可吸收给药支架减少再狭窄的方法，该方法包括提供一种药物输送生物可吸收支架，在支架的多个开口内布置一定剂量的抗再狭窄药物，但不在支架的外表面涂抹抗再狭窄药物；将支架植入患者的动脉内；并在从植入支架到基本上所有药物从支架中释放的整个给药期间，以每天支架上药物总剂量 1% 的最低释放率将抗再狭窄药物从支架输送到动脉。
• Implantable medical device with beneficial agent concentration gradient
  申请人：Conor Medsystems, Inc.

  公开号：EP2272544A1

  公开（公告）日：2011-01-12

  An implantable medical device comprises: an implantable device body having a mural surface (26) and a luminal surface (24) and a plurality of holes (20) traversing both the mural and luminal surface; a therapeutic agent, a matrix (40), and a barrier layer (30) contained in each of the plurality of holes; wherein the holes each have a luminal opening and a mural opening and the barrier layer is positioned across the luminal opening, and the therapeutic agent is primarily delivered through the mural opening of the hole; wherein the therapeutic agent is present in both the barrier layer and the matrix, at different local concentrations, and the matrix is created in a stepwise manner, such that a concentration gradient of the therapeutic agents exists in the matrix.

  一种植入式医疗设备包括具有壁面 (26) 和管腔表面 (24) 的可植入设备本体，以及穿过壁面和管腔表面的多个孔 (20)； 包含在多个孔中的治疗剂、基质 (40) 和隔离层 (30)；其中，每个孔都有一个管腔开口和一个壁面开口，阻挡层横跨管腔开口，治疗剂主要通过孔的壁面开口输送；其中，治疗剂以不同的局部浓度存在于阻挡层和基质中，基质以阶梯方式形成，从而使基质中存在治疗剂的浓度梯度。
• Anti-restenotic agents to be delivered from a stent
  申请人：Conor Medsystems, Inc.

  公开号：EP2433661A1

  公开（公告）日：2012-03-28

  The invention discloses an anti-restenotic drug to be delivered from a stent loaded with a predetermined amount of the anti-restenotic drug for use in a method of reducing restenosis, the method comprising implanting the stent having no more than the predetermined amount of the anti-restenotic drug; and delivering the anti-restenotic drug from a bioresorbable polymer matrix reservoir in the stent, wherein the polymer matrix is completely resorbed between 30 days and 90 days, inclusive, and the entire predetermined amount elutes from the stent before the polymer matrix is resorbed.

  本发明公开了一种从装载有预定量抗再狭窄药物的支架中输送抗再狭窄药物的方法，用于减少再狭窄的方法，该方法包括植入抗再狭窄药物不超过预定量的支架；以及从支架中的生物可吸收聚合物基质贮槽中输送抗再狭窄药物，其中聚合物基质在30天至90天（含90天）之间被完全吸收，在聚合物基质被吸收之前，全部预定量从支架中洗脱出来。